Pfizer company analysis

  • 5,856 views
Uploaded on

market-share analysis

market-share analysis

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
5,856
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
146
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Working for a healthier world Presented BY: Abiade Adedoyin Haley Fabricant Brian Neary
  • 2. Company timeline 1849 : the company is founded in Brooklyn, NY- by Charles Pfizer & Charles erhart 1880 : Pfizer begins manufacturing citric acid 1882: Pfizer opens offices & warehouse in Chicago, Illinois 1900: Pfizer pioneers mass-production of citric acid from Sugar by mold fermentation 1941: Pfizer Mass Produces penicillin using fermentation technology 1942: Pfizer goes public, when 240,000 shares of new common stock were offered 1950: Terramycin® antibiotic becomes the first DRUG sold in the U.S. under the Pfizer label 1951: offices open in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama, & Puerto rico 1955: The first overseas fermentation plant is opened in England. Pfizer partners with Japan's Taito to manufacture and distribute antibiotics. 1958: plants begin production in Mexico, Italy, & Turkey. Intl. personnel increases over 7,000. 1961: Pfizer establishes its new worldwide headquarters in midtown Manhattan 1971: Pfizer acquires German manufacturer mack Illertissen. 1972: Global Sales cross the billion-dollar threshold. 1995: Pfizer opens a pharmaceutical plant in China & expands markets in the Pacific Rim 1998: Pfizer's launches Viagra® (sildenafil citrate) 2000: Pfizer and Warner-Lambert merge 2003: Pfizer and Pharmacia Corp. merge.. A $7.1 billion dollar r & D budget is created. 2004: Pfizer is included in the Dow Jones Industrial Average.
  • 3. Stock Performance Pfizer Corporation Last: 26.67 7.9 % 5 Yr Income Growth 10.8 % 5 Yr Sales Growth 12.2 Forward P/E 17.6 Current P/E 2.34 FY(12/08) EPS Estimate 2.19 FY(12/07) EPS Estimate 2.67 Current EPS 188.7 Bil Market Cap 7.1 Bil Total Shares Outstanding 22.8 % Net Profit Margin 11.0 Bil Income 48.4 Bil Sales Fundamental Data
  • 4. Global sales Distribution Pfizer Australia Sydney
  • 5. International growth foreign expansion Discovery of the antibiotic, Terramycin in 1950 World war iI and Competition in the us market Foreign direct investment – series of Acquisitions and Partnerships international networks Pfizer In Europe - acquisition of Pharmacia corporation in U.K Pfizer IN THE western hemisphere - monopolistic control? Pfizer in the far east region - Partnership in Asia Pfizer in the middle east & Africa - importing, exporting & Greenfield strategy financing of foreign Efforts self-financing of its investments - internal cash flows lower debt ratio than industry average short-term loans & low interest rate advantage credit ratings – triple a Pfizer Asia Pacific Pte . Malaysia
  • 6. international operations pharmaceutical manufacturing 3 primary sectors (human medication- Animal health- consumer healthcare) 4 geographical areas (U.S.., Europe/Canada, Japan/Asia, & Latin America/Africa/Middle East) research & development 7 primary campuses (Michigan, France, California, Japan, England, New London Connecticut- the R&D headquarters) 11 therapeutic categories 2 streams of development (human consumption, & vaccines/medications for 30+ animal species) 250 partners in academia / joint ventures Pfizer Brazil sao Paulo
  • 7. international operations Marketing & distribution Central business unit Regional business units Global supply chain characteristics Animal health vaccines, medication, and healthcare products directly manages r&D, production & distribution Shares pharmaceutical supply chain network Pfizer Switzerland Marketing & Distribution
  • 8. Global Strategy & Targets 2006 Foreign Revenue: $22.5B or 46.6% 10 countries outside the U.S. with more than $500M Global revenues are 8.7% of world market Market Cap almost $50M more than nearest competitor Pfizer Senegal
  • 9. Business Strategy New Products & technologies 2006 R&D spending: $7.4B Worldwide development efforts Replace expiring patents Intellectual Property Protection Legal efforts Limiting foreign business practices GATT advances Pfizer Pakistan Manufacturing
  • 10. Business Strategy Financial Strategies International capital markets Foreign Exchange trading Political Influences Government partnering Regulatory oversight Global Coordination Chairman and former CEO Henry McKinnell with supplies donated by Pfizer to a Mobile Army Surgical Hospital